Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score
Psychiatric Times
JUNE 13, 2025
The American Psychiatric Association updated their practice guidelines for the treatment of schizophrenia in 2020 and recommended “that patients who have moderate to severe or disabling tardive dyskinesia associated with antipsychotic therapy be treated with a reversible inhibitor of the vesicular monoamine transporter 2.” How can this be?
Let's personalize your content